This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Matoba, T. Articles by Chiba, M. Search for Related Content PubMed PubMed Citation Articles by Matoba, T. Articles by Chiba, M. Social Bookmarking                         What's this?

Effects of Diltiazem on Occupational Raynaud's Syndrome (Vibration Disease)

Department of Environmental Medicine, Kurume University School of Medicine, Kurume, Japan

Michio Chiba

Department of Environmental Medicine, Kurume University School of Medicine, Kurume, Japan

An open trial on the therapeutic effect of diltiazem, a calcium antagonist, was conducted on occupational Raynaud's syndrome (vibration disease). Seventeen men with vibration disease were studied. The mean age was 54 years. No patient had cardiovascular disease. Primary and secondary cases of Raynaud's phenomenon were excluded. Diltiazem, 30mg orally 3 times daily, was given to the patients for 6 weeks. Before and after this treatment period, we evaluated the subjective symptoms (11 items including Raynaud's phenomenon, numbness of hands and arms, stiffness of shoulder and neck, and others) and peripheral function (by cold water immersion test, vibration and pain sensations for fingers, tapping test, and momentary grasp strength test), and did laboratory blood tests (12 variables). The "effective" rates of subjective symptoms evaluating by the method of 5 steps and the peripheral function was 69.6% and 52.9%, respectively. The overall effectiveness of diltiazem therapy was assessed by collectively evaluating the changes in subjective symptoms, peripheral functions, and the occurrence of side effects. No side effects occurred during the treatment period. Thus, the collective effectiveness of diltiazem was 64.7%. In conclusion, diltiazem, a calcium antagonist, can be effective in the long-term treatment of patients with vibration disease.

Angiology, Vol. 36, No. 12, 850-856 (1985)
DOI: 10.1177/000331978503601203


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Z Stoyneva, M Lyapina, D Tzvetkov, and E Vodenicharov Current pathophysiological views on vibration-induced Raynaud's phenomenon Cardiovasc Res, March 1, 2003; 57(3): 615 - 624. [Abstract] [Full Text] [PDF]